Literature DB >> 25196853

Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms.

Roland Jäger1, Ashot S Harutyunyan, Elisa Rumi, Daniela Pietra, Tiina Berg, Damla Olcaydu, Richard S Houlston, Mario Cazzola, Robert Kralovics.   

Abstract

The C allele of the rs2736100 single nucleotide polymorphism located in the second intron of the TERT gene has recently been identified as a susceptibility factor for myeloproliferative neoplasms (MPN) in the Icelandic population. Here, we evaluate the role of TERT rs2736100_C in sporadic and familial MPN in the context of the previously identified JAK2 GGCC predisposition haplotype. We have confirmed the TERT rs2736100_C association in a large cohort of Italian sporadic MPN patients. The risk conferred by TERT rs2736100_C is present in all molecular and diagnostic MPN subtypes. TERT rs2736100_C and JAK2 GGCC are independently predisposing to MPN and have an additive effect on disease risk, together explaining a large fraction of the population attributable fraction (PAF = 73.06%). We found TERT rs2736100_C significantly enriched (P = 0.0090) in familial MPN compared to sporadic MPN, suggesting that low-penetrance variants may be responsible for a substantial part of familial clustering in MPN.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25196853      PMCID: PMC4657470          DOI: 10.1002/ajh.23842

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


Introduction

Myeloproliferative neoplasms (MPN) constitute a group of phenotypically diverse chronic myeloid malignancies including three major disease entities: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Mutually exclusive oncogenic somatic mutations in three genes have been identified in more than 90% of MPN cases 1. Mutations in JAK2, most notably JAK2-V617F are present in all three disease subtypes, more frequently in PV 2–5, while MPL and CALR mutations are exclusively found in ET and PMF patients 6–8. The same somatic mutations are present also in familial MPN, which account for 5–10% of MPN cases 9–11. Previously, a common haplotype (GGCC or 46/1) at the JAK2 locus has been found to predispose to JAK2 mutation positive sporadic and familial MPN 12–15. Genome-wide association studies have successfully revealed risk loci for a series of cancers 16. A recent study identified the germline sequence variant rs2736100_C located in the second intron of the TERT gene as risk variant for MPN in the Icelandic population 17. In this study, we were seeking to confirm the TERT association in an independent cohort from a different ethnic background and evaluate the role of the TERT predisposition locus in familial clustering of MPN. Furthermore, we were testing the possibility of an interaction of TERT and JAK2 susceptibility loci in sporadic and familial MPN.

Methods

Blood samples from sporadic MPN (n = 717), familial MPN (n = 121) and control (n = 202) subjects from Italy were obtained after written informed consent. The study was approved by the institutional ethics committee (Comitato di Bioetica, Fondazione IRCCS Policlinico San Matteo) and procedures were in accordance with the Helsinki declaration. Details on patient characteristics and sample collection have been described in a previous study 15. Patients were defined as familial cases if two or more individuals within the same pedigree were affected. For each family, the proband was identified as the first affected family member seeking medical attention. Presence of the JAK2-V617F mutation, JAK2 exon 12 mutations, MPL exon 10 mutations, and CALR exon 9 mutations was assessed in granulocyte DNA as previously described 7. Genotyping for rs2736100 (TERT) and rs10974944 (JAK2) was performed using commercially available TaqMan SNP genotyping assays (C___1844009 and C__31941696, respectively; Applied Biosystems, Foster City, CA). Statistical analyses were performed using the R statistical software (version 3.0.3) 18 in conjunction with the R-packages “SNPassoc” and “scrime.” Population attributable fraction (PAF) and proportions of familial relative risk (FRR) explained by TERT and JAK2 loci were calculated as previously described by others 19,20, using an estimate of 5.6 for the overall MPN FRR 21. The Cochran–Armitage test of trend was applied to study differences in distribution of risk allele numbers per individual in the different cohorts. The absolute risk for developing MPN in different TERT/JAK2 genotypic classes was calculated using logistic regression.

Results

We confirmed the previously reported 17 association of rs2736100_C with the MPN phenotype in a cohort of sporadic MPN patients (n = 717) of a different ethnic background (Table1). The size of our sporadic MPN cohort allowed for comparison of genotype distributions in different molecular and diagnostic subgroups. Significant associations were detected for both JAK2-positive and CALR-positive MPN at similar strength (Table1), suggesting that there is no preferential susceptibility to any molecular subtype. A similar trend was observed for MPL-positive and triple negative MPN patients (lacking JAK2, MPL, and CALR mutations), however, statistical significance is absent, possibly due to low sample sizes (Supporting Information Table 1). As in the prior study 17, the TERT rs2736100_C association was present in PV, ET, and PMF, implying a general role in MPN pathogenesis (Supporting Information Table 1).
Table 1

Association of TERT rs2736100 with Sporadic and Familial MPN and Molecular Subtypes

Genotype frequency (%) case populationGenotype frequency (%) control populationOdds ratio (95% CI)
Case populationControl populationA/AA/CC/CA/AA/CC/CA/AA/CC/CP value
Sporadic MPN(n = 717)Control(n = 202)11.3(81)46.2 (331)42.5 (305)23.3 (47)43.6 (88)33.2 (67)12.18 (1.42–3.35)2.64 (1.69–4.13)1.15 × 10−4
Sporadic MPN JAK2+ (n = 516)Control (n = 202)10.7(55)44.8 (231)44.6 (230)23.3 (47)43.6 (88)33.2 (67)12.24 (1.42–3.55)2.93 (1.82–4.72)5.55 × 10−5
Sporadic MPN CALR+ (n = 126)Control (n = 202)11.9 (15)46.8 (59)41.3 (52)23.3 (47)43.6 (88)33.2 (67)12.10 (1.08–4.10)2.43 (1.23–4.82)0.0270
Familial MPN (n = 121)Control (n = 202)5.0 (6)39.7 (48)55.4 (67)23.3 (47)43.6 (88)33.2 (67)14.27 (1.7–10.72)7.83 (3.14–19.55)1.10 × 10−6
Familial MPN probands (n = 75)Control (n = 202)5.3 (4)36.0 (27)58.7 (44)23.3 (47)43.6 (88)33.2 (67)13.61 (1.19–10.92)7.72 (2.60–22.94)2.65 × 10−5
Familial MPN (n = 121)Sporadic MPN (n = 717)5.0 (6)39.7 (48)55.4 (67)11.3 (81)46.2 (331)42.5 (305)11.96 (0.81–4.73)2.97 (1.24–7.08)0.0090
Familial MPN probands (n = 75)Sporadic MPN (n = 717)5.3 (4)36.0 (27)58.7 (44)11.3 (81)46.2 (331)42.5 (305)11.65 (0.56–4.85)2.92 (1.02–8.37)0.0180
Association of TERT rs2736100 with Sporadic and Familial MPN and Molecular Subtypes We next studied the combined effects of the two known MPN risk loci at TERT and JAK2 as well as their possible interaction. Conditional logistic regression analysis revealed that TERT and JAK2 loci are independently predisposing to MPN, the total combined risk approximating the sum of the two genotypes (Fig. 1; Supporting Information Table 2). Direct testing for interaction was negative (Supporting Information Table 3). The combined effects of TERT and JAK2 risk loci are stronger in JAK2-positive MPN (Fig. 1). This finding is compatible with the JAK2 risk haplotype predisposing primarily for the acquisition of somatic mutations in the JAK2 gene.
Figure 1

Combined effects of TERT and JAK2 MPN predisposition loci. Genotypic odds ratios for MPN in respect to the nine genotypic combinations at TERT (rs2736100) and JAK2 (rs10974944) loci are shown for (A) sporadic and familial total cohorts as well as for (B) sporadic JAK2-positive and CALR-positive subcohorts. Risk alleles are marked in red. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Combined effects of TERT and JAK2 MPN predisposition loci. Genotypic odds ratios for MPN in respect to the nine genotypic combinations at TERT (rs2736100) and JAK2 (rs10974944) loci are shown for (A) sporadic and familial total cohorts as well as for (B) sporadic JAK2-positive and CALR-positive subcohorts. Risk alleles are marked in red. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.] To evaluate the role of TERT in familial MPN, we determined the rs2736100 genotype in 121 affected members of 75 Italian families with two or more MPN cases within first and/or second degree relatives. The TERT rs2736100_C association is significantly stronger in familial MPN compared to sporadic MPN (P = 0.009; Table1), indicating a role of the TERT locus in MPN familial clustering. Proband-based analysis confirmed this observation (P = 0.018; Table1). As previously reported on a smaller familial MPN cohort 15, such a significant difference in association strength is absent for JAK2 GGCC when directly comparing sporadic and unfiltered familial JAK2-positive MPN cases (Supporting Information Table 4). However, MPN families consisting of both JAK2-positive and JAK2-negative members might be confounding the possible association, as JAK2 GGCC predisposes mainly to JAK2-positive MPN. Indeed, when restricting analysis to families exclusively consisting of JAK2-positive members, we observed a significant trend toward JAK2 GGCC enrichment in familial MPN compared to sporadic MPN (P = 0.046; Supporting Information Table 4). Moreover, the familial MPN cohort exhibits enrichment for individuals carrying more than three risk alleles (counting one for heterozygotes and two for homozygotes; Supporting Information Figure 1) and a trend for odds ratios increasing toward double positive (TERT/JAK2) individuals (Supporting Information Table 2), further supporting the possibility of JAK2 GGCC contributing to MPN familial clustering. Independence of TERT and JAK2 loci in mediating MPN susceptibility, as observed in sporadic MPN, is also true for familial MPN (Fig. 1). Similar to that reported in the Icelandic study 17, in this study cohort TERT rs2736100_C is estimated to account for 51.89% of PAF. In concert with JAK2 GGCC (PAF = 44.01%), they explain a large part (combined PAF = 73.06%) of the population susceptibility for MPN. The absolute risk for developing MPN in different TERT/JAK2 genotypic classes is calculated in Supporting Information Table 5. As the risk variant rs2736100_C is present at high frequency (55%; Table1) in the general population, only 2.01% of the FRR can be attributed to the TERT rs2736100_C variation. In contrast, 5.15% of FRR can be explained by the JAK2 GGCC risk haplotype which is present at lower frequency (27%; Supporting Information Table 4) in the general population.

Discussion

The TERT gene encodes the reverse transcriptase of the telomerase complex, essential for maintaining telomere length 22. The C allele of rs2736100 has been linked to longer telomeres 23,24, compatible with a direct regulatory effect of rs2736100 genotype on TERT expression. TERT rs2736100_C was previously shown to also associate with elevated risk for several other cancers, albeit with lower effect 25–28. Furthermore, rs2736100_C is linked to increased blood cell count values 17,29, a hallmark of MPN. The fact that TERT rs2736100_C predisposes to all MPN subtypes implies a generic role in MPN predisposition, possibly through affecting blood cells counts. Enrichment of common susceptibility loci in familial forms of predominantly sporadic cancers has been reported previously 20, and contribution of low-penetrance risk loci to familial clustering is well acknowledged 19,30. Notably, both TERT rs2736100_C for all MPN subtypes as well as JAK2 GGCC for JAK2-positive MPN exhibit effect sizes stronger than typically observed for common cancer-predisposing variants 16. This might explain the significance of familial enrichment for TERT rs2736100_C (Table1). The implication of JAK2 GGCC in familial clustering remains to be confirmed in a larger set of JAK2-positive MPN families. In conclusion, common variation at TERT and JAK2 loci explains most of the population risk for developing MPN. Enrichment of the TERT risk variant in familial MPN suggests the possibility of random accumulation of several common high frequency variants being responsible for parts of the elevated risk underlying familial clustering. More common low penetrance and/or higher penetrance rare mutations remain to be discovered to explain the missing heritability in sporadic MPN and the missing excess familial risk in MPN.
  29 in total

1.  Comprehensive evaluation of the impact of 14 genetic variants on colorectal cancer phenotype and risk.

Authors:  Steven J Lubbe; Maria Chiara Di Bernardo; Peter Broderick; Ian Chandler; Richard S Houlston
Journal:  Am J Epidemiol       Date:  2011-12-07       Impact factor: 4.897

2.  The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

Authors:  Ross L Levine; Marc Loriaux; Brian J P Huntly; Mignon L Loh; Miroslav Beran; Eric Stoffregen; Roland Berger; Jennifer J Clark; Stephanie G Willis; Kim T Nguyen; Nikki J Flores; Elihu Estey; Norbert Gattermann; Scott Armstrong; A Thomas Look; James D Griffin; Olivier A Bernard; Michael C Heinrich; D Gary Gilliland; Brian Druker; Michael W N Deininger
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

3.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

4.  From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.

Authors:  Mario Cazzola; Robert Kralovics
Journal:  Blood       Date:  2014-04-30       Impact factor: 22.113

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 6.  Architecture of inherited susceptibility to common cancer.

Authors:  Olivia Fletcher; Richard S Houlston
Journal:  Nat Rev Cancer       Date:  2010-05       Impact factor: 60.716

7.  Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.

Authors:  Ola Landgren; Lynn R Goldin; Sigurdur Y Kristinsson; Elin A Helgadottir; Jan Samuelsson; Magnus Björkholm
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

8.  Lung cancer susceptibility locus at 5p15.33.

Authors:  James D McKay; Rayjean J Hung; Valerie Gaborieau; Paolo Boffetta; Amelie Chabrier; Graham Byrnes; David Zaridze; Anush Mukeria; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Dana Mates; Vladimir Bencko; Lenka Foretova; Vladimir Janout; John McLaughlin; Frances Shepherd; Alexandre Montpetit; Steven Narod; Hans E Krokan; Frank Skorpen; Maiken Bratt Elvestad; Lars Vatten; Inger Njølstad; Tomas Axelsson; Chu Chen; Gary Goodman; Matt Barnett; Melissa M Loomis; Jan Lubiñski; Joanna Matyjasik; Marcin Lener; Dorota Oszutowska; John Field; Triantafillos Liloglou; George Xinarianos; Adrian Cassidy; Paolo Vineis; Francoise Clavel-Chapelon; Domenico Palli; Rosario Tumino; Vittorio Krogh; Salvatore Panico; Carlos A González; José Ramón Quirós; Carmen Martínez; Carmen Navarro; Eva Ardanaz; Nerea Larrañaga; Kay Tee Kham; Timothy Key; H Bas Bueno-de-Mesquita; Petra Hm Peeters; Antonia Trichopoulou; Jakob Linseisen; Heiner Boeing; Göran Hallmans; Kim Overvad; Anne Tjønneland; Merethe Kumle; Elio Riboli; Diana Zelenika; Anne Boland; Marc Delepine; Mario Foglio; Doris Lechner; Fumihiko Matsuda; Helene Blanche; Ivo Gut; Simon Heath; Mark Lathrop; Paul Brennan
Journal:  Nat Genet       Date:  2008-11-02       Impact factor: 38.330

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.

Authors:  Stig E Bojesen; Karen A Pooley; Sharon E Johnatty; Jonathan Beesley; Kyriaki Michailidou; Jonathan P Tyrer; Stacey L Edwards; Hilda A Pickett; Howard C Shen; Chanel E Smart; Kristine M Hillman; Phuong L Mai; Kate Lawrenson; Michael D Stutz; Yi Lu; Rod Karevan; Nicholas Woods; Rebecca L Johnston; Juliet D French; Xiaoqing Chen; Maren Weischer; Sune F Nielsen; Melanie J Maranian; Maya Ghoussaini; Shahana Ahmed; Caroline Baynes; Manjeet K Bolla; Qin Wang; Joe Dennis; Lesley McGuffog; Daniel Barrowdale; Andrew Lee; Sue Healey; Michael Lush; Daniel C Tessier; Daniel Vincent; Françis Bacot; Ignace Vergote; Sandrina Lambrechts; Evelyn Despierre; Harvey A Risch; Anna González-Neira; Mary Anne Rossing; Guillermo Pita; Jennifer A Doherty; Nuria Alvarez; Melissa C Larson; Brooke L Fridley; Nils Schoof; Jenny Chang-Claude; Mine S Cicek; Julian Peto; Kimberly R Kalli; Annegien Broeks; Sebastian M Armasu; Marjanka K Schmidt; Linde M Braaf; Boris Winterhoff; Heli Nevanlinna; Gottfried E Konecny; Diether Lambrechts; Lisa Rogmann; Pascal Guénel; Attila Teoman; Roger L Milne; Joaquin J Garcia; Angela Cox; Vijayalakshmi Shridhar; Barbara Burwinkel; Frederik Marme; Rebecca Hein; Elinor J Sawyer; Christopher A Haiman; Shan Wang-Gohrke; Irene L Andrulis; Kirsten B Moysich; John L Hopper; Kunle Odunsi; Annika Lindblom; Graham G Giles; Hermann Brenner; Jacques Simard; Galina Lurie; Peter A Fasching; Michael E Carney; Paolo Radice; Lynne R Wilkens; Anthony Swerdlow; Marc T Goodman; Hiltrud Brauch; Montserrat Garcia-Closas; Peter Hillemanns; Robert Winqvist; Matthias Dürst; Peter Devilee; Ingo Runnebaum; Anna Jakubowska; Jan Lubinski; Arto Mannermaa; Ralf Butzow; Natalia V Bogdanova; Thilo Dörk; Liisa M Pelttari; Wei Zheng; Arto Leminen; Hoda Anton-Culver; Clareann H Bunker; Vessela Kristensen; Roberta B Ness; Kenneth Muir; Robert Edwards; Alfons Meindl; Florian Heitz; Keitaro Matsuo; Andreas du Bois; Anna H Wu; Philipp Harter; Soo-Hwang Teo; Ira Schwaab; Xiao-Ou Shu; William Blot; Satoyo Hosono; Daehee Kang; Toru Nakanishi; Mikael Hartman; Yasushi Yatabe; Ute Hamann; Beth Y Karlan; Suleeporn Sangrajrang; Susanne Krüger Kjaer; Valerie Gaborieau; Allan Jensen; Diana Eccles; Estrid Høgdall; Chen-Yang Shen; Judith Brown; Yin Ling Woo; Mitul Shah; Mat Adenan Noor Azmi; Robert Luben; Siti Zawiah Omar; Kamila Czene; Robert A Vierkant; Børge G Nordestgaard; Henrik Flyger; Celine Vachon; Janet E Olson; Xianshu Wang; Douglas A Levine; Anja Rudolph; Rachel Palmieri Weber; Dieter Flesch-Janys; Edwin Iversen; Stefan Nickels; Joellen M Schildkraut; Isabel Dos Santos Silva; Daniel W Cramer; Lorna Gibson; Kathryn L Terry; Olivia Fletcher; Allison F Vitonis; C Ellen van der Schoot; Elizabeth M Poole; Frans B L Hogervorst; Shelley S Tworoger; Jianjun Liu; Elisa V Bandera; Jingmei Li; Sara H Olson; Keith Humphreys; Irene Orlow; Carl Blomqvist; Lorna Rodriguez-Rodriguez; Kristiina Aittomäki; Helga B Salvesen; Taru A Muranen; Elisabeth Wik; Barbara Brouwers; Camilla Krakstad; Els Wauters; Mari K Halle; Hans Wildiers; Lambertus A Kiemeney; Claire Mulot; Katja K Aben; Pierre Laurent-Puig; Anne Mvan Altena; Thérèse Truong; Leon F A G Massuger; Javier Benitez; Tanja Pejovic; Jose Ignacio Arias Perez; Maureen Hoatlin; M Pilar Zamora; Linda S Cook; Sabapathy P Balasubramanian; Linda E Kelemen; Andreas Schneeweiss; Nhu D Le; Christof Sohn; Angela Brooks-Wilson; Ian Tomlinson; Michael J Kerin; Nicola Miller; Cezary Cybulski; Brian E Henderson; Janusz Menkiszak; Fredrick Schumacher; Nicolas Wentzensen; Loic Le Marchand; Hannah P Yang; Anna Marie Mulligan; Gord Glendon; Svend Aage Engelholm; Julia A Knight; Claus K Høgdall; Carmel Apicella; Martin Gore; Helen Tsimiklis; Honglin Song; Melissa C Southey; Agnes Jager; Ans M Wvan den Ouweland; Robert Brown; John W M Martens; James M Flanagan; Mieke Kriege; James Paul; Sara Margolin; Nadeem Siddiqui; Gianluca Severi; Alice S Whittemore; Laura Baglietto; Valerie McGuire; Christa Stegmaier; Weiva Sieh; Heiko Müller; Volker Arndt; France Labrèche; Yu-Tang Gao; Mark S Goldberg; Gong Yang; Martine Dumont; John R McLaughlin; Arndt Hartmann; Arif B Ekici; Matthias W Beckmann; Catherine M Phelan; Michael P Lux; Jenny Permuth-Wey; Bernard Peissel; Thomas A Sellers; Filomena Ficarazzi; Monica Barile; Argyrios Ziogas; Alan Ashworth; Aleksandra Gentry-Maharaj; Michael Jones; Susan J Ramus; Nick Orr; Usha Menon; Celeste L Pearce; Thomas Brüning; Malcolm C Pike; Yon-Dschun Ko; Jolanta Lissowska; Jonine Figueroa; Jolanta Kupryjanczyk; Stephen J Chanock; Agnieszka Dansonka-Mieszkowska; Arja Jukkola-Vuorinen; Iwona K Rzepecka; Katri Pylkäs; Mariusz Bidzinski; Saila Kauppila; Antoinette Hollestelle; Caroline Seynaeve; Rob A E M Tollenaar; Katarzyna Durda; Katarzyna Jaworska; Jaana M Hartikainen; Veli-Matti Kosma; Vesa Kataja; Natalia N Antonenkova; Jirong Long; Martha Shrubsole; Sandra Deming-Halverson; Artitaya Lophatananon; Pornthep Siriwanarangsan; Sarah Stewart-Brown; Nina Ditsch; Peter Lichtner; Rita K Schmutzler; Hidemi Ito; Hiroji Iwata; Kazuo Tajima; Chiu-Chen Tseng; Daniel O Stram; David van den Berg; Cheng Har Yip; M Kamran Ikram; Yew-Ching Teh; Hui Cai; Wei Lu; Lisa B Signorello; Qiuyin Cai; Dong-Young Noh; Keun-Young Yoo; Hui Miao; Philip Tsau-Choong Iau; Yik Ying Teo; James McKay; Charles Shapiro; Foluso Ademuyiwa; George Fountzilas; Chia-Ni Hsiung; Jyh-Cherng Yu; Ming-Feng Hou; Catherine S Healey; Craig Luccarini; Susan Peock; Dominique Stoppa-Lyonnet; Paolo Peterlongo; Timothy R Rebbeck; Marion Piedmonte; Christian F Singer; Eitan Friedman; Mads Thomassen; Kenneth Offit; Thomas V O Hansen; Susan L Neuhausen; Csilla I Szabo; Ignacio Blanco; Judy Garber; Steven A Narod; Jeffrey N Weitzel; Marco Montagna; Edith Olah; Andrew K Godwin; Drakoulis Yannoukakos; David E Goldgar; Trinidad Caldes; Evgeny N Imyanitov; Laima Tihomirova; Banu K Arun; Ian Campbell; Arjen R Mensenkamp; Christi J van Asperen; Kees E P van Roozendaal; Hanne Meijers-Heijboer; J Margriet Collée; Jan C Oosterwijk; Maartje J Hooning; Matti A Rookus; Rob B van der Luijt; Theo A Mvan Os; D Gareth Evans; Debra Frost; Elena Fineberg; Julian Barwell; Lisa Walker; M John Kennedy; Radka Platte; Rosemarie Davidson; Steve D Ellis; Trevor Cole; Brigitte Bressac-de Paillerets; Bruno Buecher; Francesca Damiola; Laurence Faivre; Marc Frenay; Olga M Sinilnikova; Olivier Caron; Sophie Giraud; Sylvie Mazoyer; Valérie Bonadona; Virginie Caux-Moncoutier; Aleksandra Toloczko-Grabarek; Jacek Gronwald; Tomasz Byrski; Amanda B Spurdle; Bernardo Bonanni; Daniela Zaffaroni; Giuseppe Giannini; Loris Bernard; Riccardo Dolcetti; Siranoush Manoukian; Norbert Arnold; Christoph Engel; Helmut Deissler; Kerstin Rhiem; Dieter Niederacher; Hansjoerg Plendl; Christian Sutter; Barbara Wappenschmidt; Ake Borg; Beatrice Melin; Johanna Rantala; Maria Soller; Katherine L Nathanson; Susan M Domchek; Gustavo C Rodriguez; Ritu Salani; Daphne Gschwantler Kaulich; Muy-Kheng Tea; Shani Shimon Paluch; Yael Laitman; Anne-Bine Skytte; Torben A Kruse; Uffe Birk Jensen; Mark Robson; Anne-Marie Gerdes; Bent Ejlertsen; Lenka Foretova; Sharon A Savage; Jenny Lester; Penny Soucy; Karoline B Kuchenbaecker; Curtis Olswold; Julie M Cunningham; Susan Slager; Vernon S Pankratz; Ed Dicks; Sunil R Lakhani; Fergus J Couch; Per Hall; Alvaro N A Monteiro; Simon A Gayther; Paul D P Pharoah; Roger R Reddel; Ellen L Goode; Mark H Greene; Douglas F Easton; Andrew Berchuck; Antonis C Antoniou; Georgia Chenevix-Trench; Alison M Dunning
Journal:  Nat Genet       Date:  2013-04       Impact factor: 38.330

View more
  18 in total

1.  Germline RBBP6 mutations in familial myeloproliferative neoplasms.

Authors:  Ashot S Harutyunyan; Roberto Giambruno; Christian Krendl; Alexey Stukalov; Thorsten Klampfl; Tiina Berg; Doris Chen; Jelena D Milosevic Feenstra; Roland Jäger; Bettina Gisslinger; Heinz Gisslinger; Elisa Rumi; Francesco Passamonti; Daniela Pietra; André C Müller; Katja Parapatics; Florian P Breitwieser; Richard Herrmann; Jacques Colinge; Keiryn L Bennett; Giulio Superti-Furga; Mario Cazzola; Emma Hammond; Robert Kralovics
Journal:  Blood       Date:  2015-11-16       Impact factor: 22.113

Review 2.  Familial MPN Predisposition.

Authors:  Tsewang Tashi; Sabina Swierczek; Josef T Prchal
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

3.  Diagnostic workflow for hereditary erythrocytosis and thrombocytosis.

Authors:  Mary Frances McMullin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

4.  CHST15 gene germline mutation is associated with the development of familial myeloproliferative neoplasms and higher transformation risk.

Authors:  Yi Chen; Yang Zhang; Zhihua Wang; Yewei Wang; Yujiao Luo; Nannan Sun; Shasha Zheng; Wenzhe Yan; Xiang Xiao; Sufang Liu; Ji Li; Hongling Peng; Yunxiao Xu; Guoyu Hu; Zhao Cheng; Guangsen Zhang
Journal:  Cell Death Dis       Date:  2022-07-07       Impact factor: 9.685

5.  Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies.

Authors:  Joseph Saliba; Cécile Saint-Martin; Antonio Di Stefano; Gaëlle Lenglet; Caroline Marty; Boris Keren; Florence Pasquier; Véronique Della Valle; Lise Secardin; Gwendoline Leroy; Emna Mahfoudhi; Sarah Grosjean; Nathalie Droin; M'boyba Diop; Philippe Dessen; Sabine Charrier; Alberta Palazzo; Jane Merlevede; Jean-Côme Meniane; Christine Delaunay-Darivon; Pascal Fuseau; Françoise Isnard; Nicole Casadevall; Eric Solary; Najet Debili; Olivier A Bernard; Hana Raslova; Albert Najman; William Vainchenker; Christine Bellanné-Chantelot; Isabelle Plo
Journal:  Nat Genet       Date:  2015-08-17       Impact factor: 38.330

6.  Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter.

Authors:  Adrian P Trifa; Andrei Cucuianu; Radu A Popp
Journal:  Case Rep Hematol       Date:  2014-11-10

7.  TERT Gene rs2736100 and rs2736098 Polymorphisms are Associated with Increased Cancer Risk: A Meta-Analysis.

Authors:  Xinyu Zhang; Yan Chen; Donglin Yan; Jing Han; Longbiao Zhu
Journal:  Biochem Genet       Date:  2021-06-28       Impact factor: 1.890

8.  A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineages.

Authors:  Xiao-hui Shen; Nan-nan Sun; Ya-fei Yin; Su-fang Liu; Xiao-liu Liu; Hong-ling Peng; Chong-wen Dai; Yun-xiao Xu; Ming-yang Deng; Yun-ya Luo; Wen-li Zheng; Guang-sen Zhang
Journal:  Oncotarget       Date:  2016-02-23

Review 9.  Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.

Authors:  Sylvie Hermouet; Edith Bigot-Corbel; Betty Gardie
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

10.  Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.

Authors:  Jean Pegliasco; Pierre Hirsch; Christophe Marzac; Françoise Isnard; Jean-Côme Meniane; Caroline Deswarte; Philippe Pellet; Céline Lemaitre; Gwendoline Leroy; Graciela Rabadan Moraes; Hélène Guermouche; Barbara Schmaltz-Panneau; Florence Pasquier; Chrystelle Colas; Patrick R Benusiglio; Odile Bera; Jean-Henri Bourhis; Eolia Brissot; Olivier Caron; Samy Chraibi; Pascale Cony-Makhoul; Christine Delaunay-Darivon; Simona Lapusan; Flore Sicre de Fontbrune; Pascal Fuseau; Albert Najman; William Vainchenker; François Delhommeau; Jean-Baptiste Micol; Isabelle Plo; Christine Bellanné-Chantelot
Journal:  Leukemia       Date:  2021-06-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.